Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that DIGITIVA™, a non-invasive digital health solution for heart failure management, has been listed with ...

Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and ...

Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory ...

The most significant changes from the previous guidelines, achieving buy-in and consensus, key trends, obstacles to achieving appropriate care, ensuring compliance with medical therapy and exercise, ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, in ...

Sep. 18, 2024 — A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a new ... Replacing Ultra-Processed Foods in Diet Reduces Type ...

A recent study conducted by the Department of Occupational and Environmental Health at Tongji Medical College, Huazhong ...

Global Enteral Nutrition Market was valued at US$ 8.64 billion in 2023 and is projected to surpass the market valuation of US$ 17.20 billion by 2032 at a CAGR of 7.95% during the forecast period ...

A study led by Manuel Vázquez Carrera, group leader at the Diabetes and Associated Metabolic Diseases Networking Biomedical Research Centre ...

The global diabetic nephropathy market revenue was around US$ 2.0 billion in 2022 and is estimated to reach US$ 3.3 billion by 2031, growing at a compound annual growth rate (CAGR) of 6% during the ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that DIGITIVAtm, a non-invasive digital health solution for heart failure management, has been listed ...

Valerie M. Harvey, MD, MPH, FAAD, founder of the Hampton Roads Center for Dermatology, highlighted the long-standing ...